|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our experimental results further demonstrate that Co-fuse can identify known driver fusion genes (e.g., IGH-MYC, IGH-WHSC1) in MM, when compared to AML samples, indicating the potential of Co-fuse to aid the discovery of yet unknown driver fusion genes through cohort comparisons.
|
29882166 |
2018 |
|
Multiple Myeloma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
By using genetically matched MM cell lines that had either high (pathological) or low (physiological) expression of MMSET, we found that MMSET-high cells had increased damage at baseline.
|
27109101 |
2016 |
|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
As a part of these translational efforts, novel drugs that inhibit oncogenic proteins overexpressed in defined molecular subgroups of the disease, such as FGFR3 and MMSET in t(4;14) MM, are currently being developed.
|
23233602 |
2012 |
|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Nearly half of these tumors are nonhyperdiploid and mostly have immunoglobulin H (IgH) translocations that involve 5 recurrent chromosomal loci, including 11q13 (cyclin D1), 6p21 (cyclin D3), 4p16 (fibroblast growth factor receptor 3 [FGFR3] and multiple myeloma SET domain [MMSET]), 16q23 (c-maf), and 20q11 (mafB).
|
15090448 |
2004 |
|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Together, our work elucidates previously unrecognized interplay between MMSET and EZH2 in myeloma oncogenesis and identifies domains to be considered when designing inhibitors of MMSET function.
|
25188243 |
2014 |
|
Multiple Myeloma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The spectrum of KRAS, NRAS, and BRAF codon mutations varied across subgroups with NRAS mutations at Q61 codon being common in hyperdiploid (HRD) and t(11;14) myeloma while being rare in MMSET and MAF.
|
28427158 |
2017 |
|
Multiple Myeloma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The t(4;14)(p16.3;q32), associated with 10-20% of cases of multiple myeloma (MM), deregulates the expression of MMSET and FGFR3.
|
15029211 |
2004 |
|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
There is a promiscuous array of nonrandom chromosomal partners (and oncogenes), with the 3 most frequent partners (11q13 [cyclin D1]; 4p16 [FGFR3 and MMSET]; 16q23 [c-maf]) involved in nearly half of MM tumors.
|
11418483 |
2001 |
|
Multiple Myeloma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
IGH-MMSET transcripts were found in 11 of the 53 (20%) MM cases and 1 of 16 (6%) cases of monoclonal gammopathy of uncertain significance.
|
10945609 |
2000 |
|
Multiple Myeloma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
From a clinical standpoint, it is critical to identify MM patients carrying the t(4;14) translocation, which is present in 15% of myelomas and is associated with dysregulation of WHSC1/MMSET and often FGFR3.
|
22160056 |
2011 |
|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
NSD2 is recruited through its PHD domain to oncogenic gene loci to drive multiple myeloma.
|
23980095 |
2013 |
|
Multiple Myeloma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We found that MMSET enhances the proliferation of MM cells by stimulating the expression of c-MYC at the post-transcriptional level.
|
22972034 |
2013 |
|
Multiple Myeloma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Markedly increased MMSET expression was found in 1 MM showing associated FGFR3 and MMSET signals on an unidentified chromosome.
|
15543617 |
2005 |
|
Multiple Myeloma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We found that ACA11, an orphan box H/ACA class small nucleolar RNA (snoRNA) encoded within an intron of WHSC1, was highly expressed in t(4;14)-positive MM and other cancers.
|
22751105 |
2012 |
|
Multiple Myeloma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
A number of non-t(4;14) cases also express MMSET consistent with this gene playing a role in myeloma pathogenesis.
|
15355895 |
2004 |
|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The multiple myeloma associated MMSET gene contributes to cellular adhesion, clonogenic growth, and tumorigenicity.
|
17942756 |
2008 |
|
Multiple Myeloma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Our data indicate that IGFBP7 expression is a marker for a specific methylation pattern in myeloma, linked to translocation t(4;14) associated MMSET expression, showing clinical features of adverse prognosis with absence of myeloma bone disease.
|
25887188 |
2015 |
|
Multiple Myeloma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Simultaneous translocations of FGFR3/MMSET and CCND1 into two different IGH alleles in multiple myeloma: lack of concurrent activation of both proto-oncogenes.
|
17498561 |
2007 |
|
Multiple Myeloma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In particular, MMSET/NSD2 selective inhibition is being pursued for therapeutic interventions against multiple myeloma (MM) cases, especially in multiple myeloma t(4;14)(p16.3;q32) translocation that is associated with a significantly worse prognosis than other MM subgroups.
|
30471851 |
2019 |
|
Multiple Myeloma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In studies of patients with multiple myeloma (MM), gene expression profiling (GEP) of myeloma cells demonstrates substantially higher expression of MMSET, FGFR3, CCND3, CCND1, MAF, and MAFB--the partner genes of 14q32 translocations--than GEP of plasma cells from healthy individuals.
|
24638926 |
2014 |
|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We have analysed a series of 80 patient samples, comprising 67 multiple myeloma (MM) cases and 13 monoclonalgammopathy of undetermined significance (MGUS) cases, using RT-PCR to detect IgH-MMSET fusions.
|
12139740 |
2002 |